Literature DB >> 24844918

Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.

Wolfgang Lilleby1, Andreas Stensvold, Alv A Dahl.   

Abstract

UNLABELLED: To compare adverse effects and toxicity in men with high-risk or locally advanced prostate cancer when adding intensity-modulated radiotherapy (IMRT) technique to the pelvis. PATIENTS AND METHODS: In this prospective follow-up study 180 patients treated with conformal radiotherapy (RAD) to the prostate and vesiculae seminales (boost volumes; PV) and long-term androgen deprivation therapy (LADT), were compared to 90 patients managed by LADT, RAD to the PV and additionally pelvic IMRT. Adverse effects were self-reported at baseline, at 3- and 12-month follow-up. At each time point, the patients rated a questionnaire covering urinary, bowel, and sexual function and bother, quality of life, fatigue, and mental distress.
RESULTS: At 3-month follow-up urinary and bowel functions were significantly decreased among IMRT compared to RAD. At 12-month follow-up both groups showed the same reductions within the urinary, bowel and sexual domains. RAD patients had more mental distress than IMRT patients. The scores on quality of life, fatigue and mental distress hardly influenced function or bother within the urinary, bowel or sexual domains.
CONCLUSIONS: Men treated for high-risk or locally advanced prostate cancer with a combination of LADT, RAD and IMRT including PV and pelvic structures had considerably more acute side effects at 3 months than men treated with LADT and RAD to the PV only. However, at 12-month follow-up, the observed genitourinary and gastrointestinal function and bother were similar in both groups.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24844918     DOI: 10.3109/0284186X.2014.916042

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Delia Ciardo; Silvia Ferrario; Piero Fossati; Giuseppe Fanetti; Dario Zerini; Davide Zannoni; Cristiana Fodor; Marianna A Gerardi; Alessia Surgo; Matteo Muto; Raffaella Cambria; Ottavio De Cobelli; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-04-25       Impact factor: 3.039

2.  Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study.

Authors:  Matthew G Parry; Arunan Sujenthiran; Thomas E Cowling; Julie Nossiter; Paul Cathcart; Noel W Clarke; Heather Payne; Jan van der Meulen; Ajay Aggarwal
Journal:  J Clin Oncol       Date:  2019-06-04       Impact factor: 44.544

3.  Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.

Authors:  Amar U Kishan; Nicholas Marco; Melanie-Birte Schulz-Jaavall; Michael L Steinberg; Phuoc T Tran; Jesus E Juarez; Audrey Dang; Donatello Telesca; Wolfgang A Lilleby; Joanne B Weidhaas
Journal:  Radiother Oncol       Date:  2022-01-03       Impact factor: 6.901

4.  Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.

Authors:  Kentaro Ishii; Ryo Ogino; Yukinari Hosokawa; Chiaki Fujioka; Wataru Okada; Ryota Nakahara; Ryu Kawamorita; Takuhito Tada; Yoshiki Hayashi; Toshifumi Nakajima
Journal:  Br J Radiol       Date:  2016-03-31       Impact factor: 3.039

5.  Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.

Authors:  Wolfgang Lilleby; Amol Narrang; Gunnar Tafjord; Ljiljana Vlatkovic; Kjell Magne Russnes; Andreas Stensvold; Knut Håkon Hole; Phuoc Tran; Karsten Eilertsen
Journal:  Radiat Oncol       Date:  2015-11-17       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.